Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease

We report a 64-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Yoshika, Iwanaga, Nozomi, Adachi, Anna, Tsunozaki, Kinuyo, Izumi, Yasumori, Moriwaki, Yuji, Kurohama, Kazuhiro, Ito, Masahiro, Kawakami, Atsushi, Migita, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700153/
https://www.ncbi.nlm.nih.gov/pubmed/26798538
http://dx.doi.org/10.1155/2015/163952
Descripción
Sumario:We report a 64-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intravenous cyclophosphamide resulted in remission of AOSD and a reduction in the high doses of steroids. Efficacy of biologics against MAS in AOSD is unclear. Cyclophosphamide, a conventional cytotoxic agent, should be considered as one of the therapeutic options for refractory types of AOSD with MAS.

Ejemplares similares